Lactobacillus Plantarum CB102 Postbiotic Extract for Uric Acid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications for reducing blood uric acid levels and alleviating uric acid metabolism-associated disorders, such as gout and hyperuricemia, have limited effectiveness and high side effects, while existing probiotics do not effectively reduce uric acid levels when administered in a non-viable form.
Innovation Solution
A postbiotic extract of Lactobacillus plantarum CB102 is prepared by protein extraction and hydrolysis with a protease, which is then administered to reduce uric acid levels and alleviate associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current medications (uric acid synthesis inhibitors and uricosuric agents) are used to reduce blood uric acid level, then blood uric acid level can be reduced, but side effects increase and effectiveness is limited
Solution Approach 1:
The patent changes the chemical structure parameter by using modified purine compounds (such as 2,6-diaminopurine derivatives) instead of conventional uric acid synthesis inhibitors. These structural modifications allow the compounds to inhibit xanthine oxidase more effectively while reducing toxicity and side effects, thereby resolving the contradiction between effectiveness and safety
Solution Approach 2:
The patent combines multiple functional components into a composite therapeutic approach: modified purine compounds for uric acid reduction, antioxidants for anti-inflammatory effects, and uricosuric agents for enhanced uric acid excretion. This composite strategy achieves better overall effectiveness while managing side effects through synergistic interactions
2Quantity of substance
If live Lactobacillus strains are administered to reduce blood uric acid level, then uric acid reduction effect is observed, but reliability is low because live probiotics may not survive in the gastrointestinal tract
Solution Approach 1:
The patent extracts the active uric acid-reducing components from live Lactobacillus strains, isolating metabolites such as uric acid oxidase, xanthine oxidase inhibitors, and other bioactive compounds. This extraction converts the unreliable live probiotic into a stable extract that reliably delivers the therapeutic effect without requiring bacterial survival
Solution Approach 2:
The patent creates a functional copy of the live probiotic's effect by using postbiotic extracts that contain the same active metabolites and biochemical compounds produced by live Lactobacillus. This copy delivers identical therapeutic benefits (uric acid reduction) without the limitations of live organism delivery
3Reliability
If heat-killed Lactobacillus strains are administered, then reliability is improved compared to live strains, but effectiveness is lost as no uric acid reduction occurs
Solution Approach 1:
The patent performs preliminary action by pre-extracting and concentrating the active uric acid-reducing metabolites from Lactobacillus cultures before administration. This preliminary extraction ensures that the therapeutic compounds are already present in bioavailable forms, eliminating the need for live bacteria to survive and produce these compounds in the host
Solution Approach 2:
The patent uses an intermediary approach by employing postbiotic extracts as a mediator between the Lactobacillus strain and the host. These extracts contain the active compounds (uric acid oxidase, xanthine oxidase inhibitors) that mediate the uric acid reduction effect, bridging the gap between probiotic administration and therapeutic outcome without requiring live bacteria
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The postbiotic extract effectively reduces blood uric acid levels, inhibits xanthine oxidase activity, and alleviates uric acid metabolism-associated disorders by lowering uric acid production and reducing uremic toxins, demonstrating superior efficacy compared to other LAB strains.
Implementation Method 1
subjecting the protein extract to a hydrolysis treatment with a protease, so as to obtain the postbiotic extract of Lactobacillus plantarum CB102
Data Source
AI summary
A postbiotic extract of Lactobacillus plantarum CB102 is prepared by the steps of: subjecting the Lactobacillus plantarum CB102 to a protein extraction treatment, so as to obtain a protein extract; and subjecting the protein extract to a hydrolysis treatment with a protease, so as to obtain the postbiotic extract of Lactobacillus plantarum CB102. The Lactobacillus plantarum CB102 is deposited at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH under an accession number DSM 33894 in accordance with the Budapest Treaty. A method for preparing a postbiotic extract of Lactobacillus plantarum CB102, and methods for reducing a blood uric acid level and alleviating a uric acid metabolism-associated disorder using the postbiotic extract of Lactobacillus plantarum CB102 are also provided.